Journal
DRUG DISCOVERY TODAY
Volume 14, Issue 17-18, Pages 876-884Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2009.06.003
Keywords
-
Categories
Ask authors/readers for more resources
Assessment of seizure risk traditionally occurs late in the drug discovery process using low-throughput, resource intensive in vivo assays. Such approaches do not allow sufficient time to mitigate risk by influencing chemical design. Early identification using cheaper, higher throughput assays with lower animal and compound requirements would be preferable. Here we review the current techniques available to assess this issue and describe how they may be combined in a rational step-wise cascade allowing more effective assessment of seizure risk.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available